نتائج البحث 2221-2230 من 21737 لعملية البحث عن WHO
... who have Bacillus-Calmette-Guerin (BCG) unresponsive disease, with either carcinoma in situ with or without Ta/T1 disease. Establishment of Preclinical ...
... who have normal risk factors in order to improve the ability to diagnose and treat these cancers. We will use information in the medical record in this ...
The purpose of this study is to explore various biomarkers in the post-treatment tissue of patients who have responded to cancer therapy and compare it to ...
The purpose of this study is to examine the microbiome and immune function in patients with active lymphoma, and in patients with a history of lymphoma who are ...
... who have failed 1-2 prior lines of therapy. The primary objectives are to determine the maximum tolerated dose (MTD) or highest protocol-defined dose (HPDD); ...
... who have progressed after exhaustion of standard of care (SOC) or a SOC is not available. التصفّح دراسات سريرية. السابقالصفحة السابقة · توجّه للصفحة 2828 · توجّه ...
... who have previously received 177Lu-DOTATATE for midgut neuroendocrine tumor (NET) that has spread from where it first started (primary site) to other places ...
... who have received at least two prior lines of therapies. The study has 2 Modules: Module 1 for FL and Module 2 for DLBCL. Global Cardio Oncology Registry.
The purpose of this study is to monitor T cell responses from patients with advanced cancer who are being treated with an anti-PD (programmed death)-1 ...
Also, to improve disease control by decreasing the number of spinal relapses for patients who achieve a complete response (CR) or partial response (PR) and ...
لا تُقدم Mayo Clinic الدعم للشركات أو المنتجات المُعلَّن عنها هنا. لكن تدعم العائدات الإعلانية رسالتنا غير الربحية.
تحقق من هذه الكتب الأكثر مبيعًا والعروض الخاصة على الكتب والنشرات الإخبارية من Mayo Clinic Press.
تساهم التبرّعات، وهي قابلة للخصم الضريبي، في دعم آخر التطورات في الأبحاث وطرق الرعاية لإحداث نقلة نوعية في الطب.